Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hafiz Khalid

Internal Medicine Rockford, IL Medical Doctor

NPI 1154757607 CMS profile 7446

1340 Charles St Ste 300, Rockford, IL 61104

Open in the dashboard

General payments

$4,342

196 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hafiz Khalid of Rockford, IL is reported in the CMS Open Payments database as having received $4,342 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $156 1
2024 General $144 5
2023 General $360 14
2022 General $1,341 67
2021 General $1,123 55
2020 General $856 38
2019 General $362 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hafiz Khalid
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hafiz Khalid were reported at $156. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hafiz Khalid Internal Medicine median Middle half National median
2019 $362 $159 $48–$570 $163
2020 $856 $119 $33–$402 $114
2021 $1,123 $135 $37–$521 $132
2022 $1,341 $141 $42–$496 $149
2023 $360 $149 $45–$519 $160
2024 $144 $154 $47–$537 $164
2025 $156 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Actelion Pharmaceuticals US, Inc. $722 46 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $561 20 payments
  3. Novartis Pharmaceuticals Corporation $382 18 payments
  4. Janssen Pharmaceuticals, Inc $350 13 payments
  5. AstraZeneca Pharmaceuticals LP $327 19 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $253 12 payments
  7. Abbott Laboratories $201 3 payments
  8. Amgen Inc. $195 11 payments
  9. E.R. Squibb & Sons, L.L.C. $194 11 payments
  10. Medtronic, Inc. $137 5 payments
  11. Other $1,020 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,171 194 payments
  2. Education $171 2 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $722 46 payments
  2. LifeVest $561 20 payments
  3. XARELTO $350 13 payments
  4. BRILINTA $307 18 payments
  5. ENTRESTO $302 14 payments
  6. JARDIANCE $253 12 payments
  7. Repatha $195 11 payments
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $156 1 payment
  9. Impella $136 4 payments
  10. AccuCinch $134 1 payment
  11. Other $1,250 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

1,373

Median for Internal Medicine: 777

Drug cost

$196,953

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 70 $73,716
Repatha Sureclick Evolocumab Brand 20 $32,612
Xarelto Rivaroxaban Brand 29 $29,696
Entresto Sacubitril/Valsartan Brand 13 $20,860
Jardiance Empagliflozin Brand 12 $16,792
Brilinta Ticagrelor Brand 13 $13,120
Metoprolol Succinate Generic 206 $2,347
Atorvastatin Calcium Generic 204 $1,532
Ezetimibe Generic 42 $1,156
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 58 $783

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$30,449

Medicare's payments for the services billed

Medicare patients

226

Average age 75

Services billed

494

120 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 54%
Arthritis 52%
Heart failure 41%
Diabetes 40%
Atrial fibrillation 38%
Chronic kidney disease 38%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record